Fenofibrate and pioglitazone do not ameliorate the altered vascular reactivity in aorta of isoproterenol-treated rats

Journal of Cardiovascular Pharmacology

Volumn 52, Issue 5, 2008, Pages 413-421

  Fukuda, Lívia Emy ^a   Davel, Ana Paula Couto ^a   Verissimo Filho, Sidney ^b   Lopes, Lucia Rossetti ^b   Cachofeiro, Victoria ^c   Lahera, Vicente ^c   Rossoni, Luciana Venturini ^a,b  

^a Department of Physiological and Biophysical Sciences ^*  (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Aorta; Endothelium; Fenofibrate; Isoproterenol; Pioglitazone; PPAR

Indexed keywords

FENOFIBRATE; ISOPRENALINE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHENYLEPHRINE; PIOGLITAZONE; SUPEROXIDE; SUPEROXIDE DISMUTASE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; POTASSIUM CHLORIDE; VASOCONSTRICTOR AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; BLOOD VESSEL REACTIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SENSITIVITY ANALYSIS; VASCULAR RING; VASOCONSTRICTION; ANIMAL; DOSE RESPONSE; DRUG POTENTIATION; PATHOPHYSIOLOGY; PHYSIOLOGY; THORACIC AORTA; VASCULAR ENDOTHELIUM; VASODILATATION; WISTAR RAT;

ADRENERGIC BETA-AGONISTS; ANIMALS; AORTA, THORACIC; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; ISOPROTERENOL; MALE; NG-NITROARGININE METHYL ESTER; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; POTASSIUM CHLORIDE; PPAR ALPHA; PPAR GAMMA; PROCETOFEN; RATS; RATS, WISTAR; SUPEROXIDE DISMUTASE; THIAZOLIDINEDIONES; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS; VASODILATION;

EID: 59449107765     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31818a8927     Document Type: Article

References (48)

1. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature. 1990;347: 645-650.
2. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev. 1999;20:649-688.
3. Braissant O, Foufelle F, Scotto C, et al. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology. 1996; 137:354-366.
4. Marx N, Duez H, Fruchart JC, et al. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res. 2004;94:1168-1178.
5. Bishop-Bailey D. Peroxisome proliferator-activated receptors in the cardiovascular system. Br J Pharmacol. 2000;129:823-834.
6. Schiffrin EL. Peroxisome proliferator-activated receptors and cardiovascular remodeling. Am J Physiol Heart Circ Physiol. 2005;288:H1037-H1043.
7. Iglarz M, Touyz RM, Amiri F, et al. Effect of peroxisome proliferator-activated receptor-alpha and -gamma activators on vascular remodeling in endothelin-dependent hypertension. Arterioscler Thromb Vasc Biol. 2003; 23:45-51.
8. Majithiya JB, Paramar AN, Balaraman R. Pioglitazone, a PPARgamma agonist, restores endothelial function in aorta of streptozotocin-induced diabetic rats. Cardiovasc Res. 2005;66:150-161.
9. Frantz S, Hu K, Widder J, et al. Peroxisome proliferator activated-receptor agonism and left ventricular remodeling in mice with chronic myocardial infarction. Br J Pharmacol. 2004;141:9-14.
10. Blanco-Rivero J, Marquez-Rodas I, Xavier FE, et al. Long-term fenofibrate treatment impairs endothelium-dependent dilation to acetyl-choline by altering the cyclooxygenase pathway. Cardiovasc Res. 2007; 75:398-407.
11. von der Thusen JH, Kuiper J, van Berkel TJ, et al. Interleukins in atherosclerosis: molecular pathways and therapeutic potential. Pharmacol Rev. 2003;55:133-166.
12. Vila E, Salaices M. Cytokines and vascular reactivity in resistance arteries. Am J Physiol Heart Circ Physiol. 2005;288:H1016-H1021.
13. Jimenez-Altayo F, Briones AM, Giraldo J, et al. Increased superoxide anion production by interleukin-1beta impairs nitric oxide-mediated relaxation in resistance arteries. J Pharmacol Exp Ther. 2006;316:42-52.
14. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999; 340:115-126.
15. Sanz-Rosa D, Oubina MP, Cediel E, et al. Effect of AT1- receptor antagonis on vascular and circulating inflammatory mediators in SHR: role of NF-κB/ iκB system. Am J Physiol Heart Circ Physiol. 2005;288: H111-H115.
16. Rona G, Chappel CT, Balazs T, et al. An infarct like myocardial lesion and other true menifestation produced by isoproterenol in the rat. Arch Path. 1959;67:443-435.
17. Vassallo DV, Vasquez EC, Cabral AM. Contractile performance of papillary muscles of renovascular hypertensive and isoproterenol-pretreated rats. Pharmacol Res Commun. 1988;20:61-72.
18. Davel AP, Kawamoto EM, Scavone C, et al. Changes in vascular reativicty following administration of isoproterenol for one week: A role for endothelial modulation. Br J Pharmacol. 2006;148:629-639.
19. Davel AP, Fukuda LE, Sá LL, et al. Effects of isoproterenol- treatment for 7 days on inflammatory mediators in rat aorta. Am J Physiol Heart Circ Physiol. 2008;295:H211-H219.
20. Diep QN, Benkirane K, Amiri F, et al. PPAR-α activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats. J Mol Cell Cardiol. 2004;36:295-304.
21. Nagisa Y, Kato K, Watanabe K, et al. Changes in glycated haemoglobin levels in diabetic rats measured with an automatic affinity HPLC. Clin Exp Pharmacol Physiol. 2003;30:752-758.
22. Gaillard V, Casellas D, Seguin-Devaux C, et al. Pioglitazone improves aortic wall elasticity in a rat model of elastocalcinotic arteriosclerosis. Hypertension. 2005;46:372-379.
23. Desouza CV, Murthy SN, Diez J, et al. Differential effects of peroxisome proliferator activator receptor-alpha and gamma ligands on intimal hyperplasia after balloon catheter-induced vascular injury in Zucker rats. J Cardiovasc Pharmacol Ther. 2003;8:297-305.
24. Rossoni LV, Salaices M, Miguel M, et al. Ouabain-induced hypertension is accompanied by increases in endothelial vasodilator factors. Am J Physiol Heart Circ Physiol. 2002;283:H2110-H2118.
25. Staels B, Koenig W, Habib A, et al. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature. 1998;393:790-793.
26. Goetze S, Xi XP, Kawano H, et al. PPAR gamma-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells. J Cardiovasc Pharmacol. 1999;33:798-806.
27. Takano H, Nagai T, Asakawa M, et al. Peroxisome proliferator-activated receptor activators inhibit lipopolysaccharide-induced tumor necrosis factor-alpha expression in neonatal rat cardiac myocytes. Circ Res. 2000; 87:596-602.
28. Delerive P, De Bosscher K, Besnard S, et al. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem. 1999;274:32048-32054.
29. De Martin R, Hoeth M, Hofer-Warbinek R, et al. The transcription factor NF-kappa B and the regulation of vascular cell function. Arterioscler Thromb Vasc Biol. 2000;20:E83-E88.
30. Diep QN, Amiri F, Touyz RM, et al. PPARalpha activator effects on Ang II-induced vascular oxidative stress and inflammation. Hypertension. 2002;40:866-871
31. De Ciuceis C, Amiri F, Iglarz M, et al. Synergistic vascular protective effects of combined low doses of PPARalpha and PPARgamma activators in angiotensin II-induced hypertension in rats. Br J Pharmacol. 2007;151: 45-53.
32. Diep QN, Mabrouk ME, Cohn JS, et al. Structure, Endothelial Function, Cell Growth, and Inflammation in Blood Vessels of Angiotensin II- Infused Rats Role of Peroxisome Proliferator-Activated Receptor-γ. Circulation. 2002;105:2296-2302.
33. Kapetanovic IM, Krishnaraj R, Martin-Jimenez T, et al. Effects of oral dosing paradigms (gavage versus diet) on pharmacokinetics and pharmacodynamics. Chem Biol Interact. 2006;164:68-75.
34. Calnek DS, Mazzella L, Roser S, et al. Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol. 2003;23:52-57.
35. Goya K, Sumitani S, Xu X, et al. Peroxisome proliferator-activated receptor alpha agonists increase nitric oxide synthase expression in vascular endothelial cells. Arterioscler Thromb Vasc Biol. 2004;24:658-663.
36. Wang Y, Wang Y, Yang Q, et al. Effects of bezafibrate on the expression of endothelial nitric oxide synthase gene and its mechanisms in cultured bovine endothelial cells. Atherosclerosis. 2006;187:265-273.
37. Kanie N, Matsumoto T, Kobayashi T, et al. Relationship between peroxisome proliferator-activated receptors (PPAR alpha and PPAR gamma) and endothelium-dependent relaxation in streptozotocin-induced diabetic rats. Br J Pharmacol. 2003;140:23-32.
38. Li JM, Shah AM. Endothelial cell superoxide generation: regulation and relevance for cardiovascular pathophysiology. Am J Physiol Regul Integr Comp Physiol. 2004;287:R1014-R1030.
39. Landmesser U, Harrison DG, Drexler H. Oxidant stress-a major cause of reduced endothelial nitric oxide availability in cardiovascular disease. Eur J Clin Pharmacol. 2006;62(Suppl 13):13-19.
40. Inoue I, Goto S, Matsunaga T, et al. The ligands/activators for peroxisome proliferator-activated receptor alpha (PPARalpha) and PPARgamma increase Cu2+, Zn2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells. Metabolism. 2001;50: 3-11.
41. Hwang J, Kleinhenz DJ, Lassegue B, et al. Peroxisome proliferator- activated receptor-gamma ligands regulate endothelial membrane super-oxide production. Am J Physiol Cell Physiol. 2005;288:C899-C905.
42. Gouni-Berthold I, Berthold HK, Weber AA, et al. Troglitazone and rosiglitazone induce apoptosis of vascular smooth muscle cells through an extracellular signal-regulated kinase-independent pathway. Naunyn Schmiedebergs Arch Pharmacol. 2001;363:215-221.
43. Narayanan PK, Hart T, Elcock F, et al. Troglitazone-induced intracellular oxidative stress in rat hepatoma cells: A flow cytometric assessment. Cytometry A. 2003;52A:28-35.
44. Robinson JG. Update on PPAR agonists: The clinical significance of FIELD and PROACTIVE. Curr Atheroscler Rep. 2007;9:64-71.
45. Corti R, Osende J, Hutter R, et al. Fenofibrate induces plaque regression in hypercholesterolemic atherosclerotic rabbits: In vivo demonstration by high-resolution MRI. Atherosclerosis. 2007;190:106-113.
46. Walker AB, Chattington PD, Buckingham RE, et al. The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. Diabetes. 1999; 48:1448-1453.
47. Naderali EK, Fatani S, Williams G. Fenofibrate lowers adiposity and corrects metabolic abnormalities, but only partially restores endothelial function in dietary obese rats. Atherosclerosis. 2004;177:307-312.
48. Nissen SE, Wolski K. Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes. N Engl J Med. 2007; 356:2457-2471.